ACTRN12605000389606已完成3 期
A randomised phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer
Australia and New Zealand Breast Cancer Trials Group Ltd0 个研究点目标入组 5,800 人开始时间: 2005年9月14日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •Postmenopausal women with completely resected, histologically proven, hormone receptor-positive primary breast cancer who have a minimum life expectancy of 5 years and are accessible for follow up.
排除标准
- •Premenopausal women; patients with only receptor negative primary tumours; patients with locally recurrent or metastatic breast cancer; patients with history of other (non-breast) malignancies; patients receiving concurrent hormonal therapy with estrogens, progesterones, androgens, or SERMs; patients having received prior treatment with a recognised aromatase inhibitor; any prior treatment with tamoxifen or SERMS other than raloxifene; any prior treatment with hormones or steroids if not discontinued at least 3 weeks prior to randomization; patients with a prior diagnosis of an in-situ carcinoma in the contralateral breast treated with partial mastectomy and/or hormonal therapy.
研究者
相似试验
进行中（未招募）
1 期
A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer - MA.27Post-menopausal women, histologically or cytologically confirmed, receptor-positive,adequately excised, primary breast cancerEUCTR2005-001893-28-HUInternational Breast Cancer Study Group (IBCSG)7,576
进行中（未招募）
1 期
A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer - MA.27EUCTR2005-001893-28-BEInternational Breast Cancer Study Group (IBCSG)5,800
已完成
不适用
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast CancerPER-062-06INTERNATIONAL BREAST CANCER STUDY GROUP - IBCSG,
进行中（未招募）
不适用
Tamoxifen and Exemestane Trial (TEXT)Premenopausal women with histologically proven, resected breast cancer with ERand/or PgR positive tumorsMedDRA version: 14.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-000168-28-SEInternational Breast Cancer Study Group (IBCSG)2,639
进行中（未招募）
1 期
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer - Tamoxifen and Exemestane Trial (TEXT)Premenopausal women with histologically proven, resected breast cancer with ERand/or PgR positive tumorsMedDRA version: 19.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-000168-28-DEGBG Forschungs GmbH2,639